• 1
    Prevention of Diabetes Mellitus. Report of a WHO Study Group. Technical Report Series, 844. Geneva: WHO, 1994.
  • 2
    Alberti KGMM & Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15: 53953.
  • 3
    Kosaka K, Kuzuya T, Akanuma Y, Hagura R. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia 1980; 18: 238.
  • 4
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28: 4129.
  • 5
    Reaven G & Dray J. Effect of chlorpropamide on serum glucose and immunoreactive insulin concentrations in patients with maturity-onset diabetes mellitus. Diabetes 1967; 15: 48792.
  • 6
    Beck-Nielsen H, Hother-Hielsen O, Pederson O. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview. Diabet Med 1988; 5: 61320.
  • 7
    UKPDS Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 83753.
  • 8
    Safran MA & Vinicor F. The war against diabetes. How will we know if we are winning? Diabetes Care 1999; 22: 50816.